TICAGRELOR vs PLACEBO: Composite of Subsequent Stroke or Death
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0549 | 0.0492 | 0.0612 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0659 | 0.0596 | 0.0728 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.011 | -0.02 | -0.00214 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.832 | 0.718 | 0.965 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.823 | 0.703 | 0.963 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on TICAGRELOR than on PLACEBO | 90.6 | 50.1 | 467 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | TICAGRELOR | Ticagrelor 180 mg day 1, followed by 90 mg twice daily day 2-30 | 303 | 5,523 | OG000 | ClinicalTrials.gov |
| Group 2 | PLACEBO | Placebo 180 mg day 1, followed by 90 mg twice daily day 2-30 | 362 | 5,493 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | PRIMARY | ClinicalTrials.gov |
| Title | Composite of Subsequent Stroke or Death | ClinicalTrials.gov |
| Description | Participants with subsequent stroke or death | ClinicalTrials.gov |
| Time frame | From randomisation (day 1) to visit 3 (day 30-34) | ClinicalTrials.gov |
| Population | Full analysis set including all randomised patients | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death | ClinicalTrials.gov |
| NCT number | NCT03354429 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Acute Ischaemic Stroke, Transient Ischaemic Attack | ClinicalTrials.gov |
| Interventions | Ticagrelor, Placebo | ClinicalTrials.gov |
| Lead sponsor | AstraZeneca | ClinicalTrials.gov |
| Results first posted | 2020-12-22 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT03354429?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.